Novo Nordisk's operating profit increased by 15% in the first quarter of 2010
- Details
- Category: Novo Nordisk
Reported operating profit increased by 15% to DKK 4,382 million. Adjusted for the impact from currencies, operating profit in local currencies increased by around 20%.
Novartis healthcare portfolio generates strong growth in first quarter of 2010
- Details
- Category: Novartis
Novartis delivered a strong performance in the first quarter of 2010 - particularly the rapid expansion of recently launched products and important regulatory approvals achieved for new medicines and vaccines - as the Group made progress with a sharp focus on innovation, growth and productivity.
World Bank and Pfizer Announce Initiative to Help Improve Healthcare Delivery
- Details
- Category: Pfizer
The World Bank and Pfizer Inc. announced they will collaborate to improve the healthcare infrastructure, specifically the supply chain, in developing countries, starting with Africa.
Superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin)
- Details
- Category: Novo Nordisk
The Lancet published online the results of the first study comparing the once-daily human GLP-1 analogue, Victoza® (liraglutide) with a DPP-4 inhibitor, Januvia®. The 26-week trial showed that Victoza® produced significantly greater reductions in HbA1c, fasting plasma glucose (FPG) and body weight than Januvia®, with similar or better overall treatment satisfaction.[1]
Pfizer Discontinues Phase 3 Trial of Sutent® in Advanced Hepatocellular Carcinoma
- Details
- Category: Pfizer
Pfizer Inc. announced the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma (HCC), or liver cancer.
Amgen's First Quarter 2010 Revenue Increased 9 Percent to $3.6 Billion
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.30 for the first quarter of 2010, an increase of 20 percent compared to $1.08 for the first quarter of 2009.
Abbott Reports Strong First Quarter Results
- Details
- Category: Abbott
Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2010. Worldwide sales increased 14.6 percent to $7.7 billion, including a favorable 4.1 percent effect of exchange rates.
More Pharma News ...
- Sandoz to acquire Oriel Therapeutics, gaining rights to portfolio of respiratory products
- Bayer HealthCare Marks 2010 World Hemophilia Day with EUR 250,000 Contribution
- Novo Nordisk launches international survey into the psychosocial effects of living with haemophilia
- Long-term efficacy and tolerability of Vimpat® (lacosamide)
- Stemgent and Pfizer Announce Collaboration
- Roche acquires Medingo Ltd. and expands its position in the growing insulin delivery systems market
- Additional Alemtuzumab Mechanism of Action Data Reported